Keynote Address

Keynote Address
Doug Hanahan, PhD – Ludwig Institute for Cancer Research, Lausanne Branch/Swiss Federal Institute of Technology Lausanne (EPFL)/Swiss Cancer Center Leman (SCCL)

Session I: Novel Insights to the TME in IO Response

Faculty Presentation #1

Session II: Aging and Sex Hormones and Other Factors that Influence Immunotherapy Response

Faculty Presentation #1

Session III: Cutting Edge Clinical Trials with Novel Immunotherapy Targets

Faculty Presentation #1

Workshop: Integrating Spatial-Omics in IO/Single Cell Analysis

Session IV: Impact of Gut, Tumor and Other Microbes on Cancer Development and Therapy Response

Co-Chairs:
Abbigail Overacre-Delgoffe, PhD – University of Pittsburgh
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

Session V: Immune-Related Toxicity and COVID

Co-Chairs:
E. John Wherry, PhD – University of Pennsylvania
TBD

Faculty Presentation #1

Session VI: Novel Insights into Adoptive Cell Therapy

Co-Chairs:
Francesco Marincola, MD – Kite, A Gilead Company
Avery Posey, PhD – University of Pennsylvania Perelman School of Medicine

Faculty Presentation #1

Workshop: Career Development Across the Continuum: How to Effectively Prepare Grants, Manuscripts and Presentations

Session VII: Pre-Cancer Interception/Prevention

Co-Chairs:
Eduardo Vilar-Sanchez, MD, PhD – The University of Texas MD Anderson Cancer Center
TBD

Session VIII: Insights from Non-Tumor Sites in IO Response

Co-Chairs:
Matt Spitzer, PhD – University of California, San Francisco

Session IX: Immuno-Metabolism and Immunotherapy Response

Co-Chairs:
Jeffery Rathmell, PhD – Vanderbilt University Medical Center
Luke O’Neill, PhD – Trinity College Dublin